Efficacy and safety of drug-eluting beads bronchial arterial chemoembolization versus conventional bronchial arterial chemoembolization in lung cancer patients with hemoptysis

Fu, Zhe; Wang, Chunyan; Wei, Wei; Xiang, Guangming; Guan, Li; Zhan, Mei; Li, Wentian; Peng, Xiaogang; Gong, Zheng; Gao, Baoan

doi:10.2217/fon-2021-1515

Cited by 9 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DEB-BACE is also more effective than cBACE in the treatment of intermediate to advanced lung cancer, with better ORR and PFS observed, and the safety profile of this treatment modality is very good ( 7 ). DEB-BACE has also demonstrated good clinical results in treating lung cancer patients with hemoptysis, with the dual purpose of hemostasis and tumor control ( 38 ). Some studies have also used DEB-BACE in the neoadjuvant treatment of SCC ( 39 ), with excellent results, and small cell lung cancer, with good results in terms of recurrent/refractory SCLC ( 40 ).…”

Section: Discussionmentioning

confidence: 99%

Drug-eluting beads bronchial arterial chemoembolization vs. conventional bronchial arterial chemoembolization in the treatment of advanced non-small cell lung cancer

Shen

Chen

et al. 2023

Front. Med.

View full text Add to dashboard Cite

PurposeTo compare the effectiveness and safety of drug-eluting bead bronchial artery chemoembolization (DEB-BACE) with conventional bronchial artery chemoembolization (cBACE) and provide a novel treatment option for advanced non-small cell lung cancer (NSCLC).MethodsPatients with advanced NSCLC underwent DEB-BACE or cBACE and were screened retrospectively. Progression-free survival (PFS) and overall survival (OS) were the primary outcome indicators, while technical success rate, objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) were the secondary ones.ResultsA total of 41 patients were enrolled in the study, 12 in the DEB-BACE group and 29 in the cBACE group, according to the treatment regimen. No patient achieved complete response. Eighteen patients achieved partial response (9 in each group), 15 patients achieved stable disease (3 in the DEB-BACE group and 12 in the cBACE group), and eight patients achieved progressive disease (all in the cBACE group) when treated for 2 months. The overall ORR and DCR were 43.9% (18/41) and 80.5% (33/41), respectively. ORR and DCR in the DEB-BACE group were 50.0% (9/12) and 100.0% (12/12), respectively, while ORR and DCR in the cBACE group were 31.0% (9/29) and 72.4% (21/29), respectively. Compared to cBACE, the ORR and DCR of DEB-BACE were significantly improved (p < 0.05). The median PFS was better in the DEB-BACE group than in the cBACE group (6.95 months vs. 3.20 months, respectively, Hazard Ratio [HR] = 0.416; p = 0.005). Furthermore, the median OS was significantly better in the DEB-BACE group than in the cBACE group (28.5 months vs. 22.5 months, respectively, HR = 0.316; p = 0.020).ConclusionDEB-BACE has a good safety and therapeutic profile in advanced NSCLC and is superior to cBACE. DEB-BACE can be used as an alternative treatment option for advanced NSCLC, even in elderly patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug-eluting beads bronchial arterial chemoembolization vs. conventional bronchial arterial chemoembolization in the treatment of advanced non-small cell lung cancer

Shen

Chen

et al. 2023

Front. Med.

View full text Add to dashboard Cite

show abstract

“…91,92 A recent retrospective study analyzed 36 patients with lung cancer and hemoptysis who were treated by either DEB-BACE or conventional BACE (cBACE). 68 The analysis found that while there were no significant differences in the technical and clinical successes of hemoptysis treatment (P > .050), DEB-BACE was associated with increased total clinical response (P = .021), greater objective response rate (P = .035), and greater hemoptysis relapsefree survival (P = .013) when compared to cBACE. Additionally, there were no significant differences in the rates of adverse events between the 2 modalities.…”

Section: Transbronchial Artery Transarterial Therapiesmentioning

confidence: 92%

“…65,66 Until recently, however, image-guided catheter-based transarterial delivery have adapted from liver cancer management and developed transarterial chemoembolization (TACE), a technique performed to embolize tumor feeding pulmonary or bronchial arteries while delivering local chemotherapy, either via beads or mixed with lipiodol, to not only control hemoptysis but also the underlying lung malignancy. [67][68][69] However, one of the main downsides of conventional TACE (cTACE) is that by utilizing emulsions of lipiodol, the chemotherapy does not reside for long, and local concentrations are reduced, increasing the risk of systemic adverse effects. 67,70 Drug-eluting beads TACE (DEB-TACE), a recent novel technique, aims to solve this problem by taking advantage of the slow and sustained release of the chemotherapy from the beads into the local tumor environment.…”

Section: Transarterial Therapies For Lung Cancersmentioning

confidence: 99%

Image-Guided Percutaneous and Transarterial Therapies for Primary and Metastatic Lung Cancer

Mansur

Garg

Camacho

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer mortality in the world. A significant proportion of patients with lung cancer are not candidates for surgery and must resort to other treatment alternatives. Rapid technological advancements in fields like interventional radiology have paved the way for valid treatment modalities like image-guided percutaneous and transarterial therapies for treatment of both primary and metastatic lung cancer. The rationale of ablative therapies relies on the fact that focused delivery of energy induces tumor destruction and pathological necrosis. Image-guided percutaneous thermal ablation therapies are established techniques in the local treatment of hepatic, renal, bone, thyroid, or uterine lesions. In the lung, the 3 main indications for lung ablation include local curative intent, a strategy to achieve a chemoholiday in oligometastatic disease, and recently, oligoprogressive disease. Transarterial therapies include a set of catheter-based treatments that involve delivering embolic and/or chemotherapeutic agents directed into the target tumor via the supplying arteries. This article provides a comprehensive review of the various techniques available and discusses their applications and associated complications in primary and metastatic lung cancer.

show abstract

“…Ever since Viamonte's pioneering bronchial artery angiography in 1964, a growing array of local intervention treatments, including bronchial artery embolization and chemoembolization, have emerged, instilling hope for the survival of lung cancer patients (16)(17)(18). In recent years, interventional therapy technologies have been widely applied in lung cancer treatment, offering advantages such as minimally invasive procedures, minimal adverse reactions, precise therapeutic outcomes, and repeatability.…”

Section: Introductionmentioning

confidence: 99%

Bronchial artery chemoembolization in the treatment of refractory central lung cancer with atelectasis

Liu,

Zhang,

Zhang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThis study aims to explore the clinical application of bronchial artery chemoembolization (BACE) in managing refractory central lung cancer with atelectasis.MethodsThe retrospective case series includes patients diagnosed with refractory central lung cancer and atelectasis who underwent BACE treatment at Yueyang Integrated Traditional Chinese and Western Medicine Hospital, affiliated with Shanghai University of Traditional Chinese Medicine, from January 2012 to December 2021.ResultsAll 30 patients with lung cancer successfully underwent BACE procedures. Their ages ranged from 62 to 88 years, with an average age of 67.53. The treatment interval was 21 days, and the treatment cycle ranged from 2 to 12 times, averaging 4.13 times. During the BACE procedures, the Karnofsky Performance Status (KPS) score after 2 to 3 BACE cycles showed a significant improvement (82.0 ± 10.1 vs 68.3 ± 14.0, P < 0.001) than that of before BACE. Only nutritional support and symptomatic treatment were performed after BACE, and no major hemoptysis were observed. During follow-up, 23 cases resulted in mortality, while seven survived. The median progression-free survival (PFS) and overall survival (OS) were 7.0 (95% CI: 4.6–9.4) and 10.0 (95% CI: 6.2–13.8) months, respectively, with 1-, 2-, and 3-year survival rates of 84.0%, 53.5%, and 11.3%, respectively. Eight cases exhibited bronchial recanalization and relief of atelectasis. According to the RECIST scale, there were 4 cases of complete response (CR), 16 cases of partial response (PR), 9 cases of stable disease (SD), and 1 case of progressive disease (PD). No serious adverse events were reported.ConclusionBACE might be a safe intervention for refractory central lung cancer accompanied by atelectasis. The procedure exhibits satisfactory outcomes in tumor control, atelectasis relief, and enhancement of quality of life, warranting further investigation.

show abstract

Efficacy and safety of drug-eluting beads bronchial arterial chemoembolization versus conventional bronchial arterial chemoembolization in lung cancer patients with hemoptysis

Cited by 9 publications

References 18 publications

Drug-eluting beads bronchial arterial chemoembolization vs. conventional bronchial arterial chemoembolization in the treatment of advanced non-small cell lung cancer

Drug-eluting beads bronchial arterial chemoembolization vs. conventional bronchial arterial chemoembolization in the treatment of advanced non-small cell lung cancer

Image-Guided Percutaneous and Transarterial Therapies for Primary and Metastatic Lung Cancer

Bronchial artery chemoembolization in the treatment of refractory central lung cancer with atelectasis

Contact Info

Product

Resources

About